• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ARGONAUT-I 研究:头孢他啶罗(S-649266),一种新型的具有铁载体结构的头孢菌素,对革兰氏阴性菌的活性,包括碳青霉烯类耐药非发酵菌和具有明确的扩展谱β-内酰胺酶和碳青霉烯酶。

ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and with Defined Extended-Spectrum β-Lactamases and Carbapenemases.

机构信息

Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA

Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.

出版信息

Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01801-18. Print 2019 Jan.

DOI:10.1128/AAC.01801-18
PMID:30323050
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6325197/
Abstract

The activity of the siderophore cephalosporin cefiderocol is targeted against carbapenem-resistant Gram-negative bacteria. In this study, the activity of cefiderocol against characterized carbapenem-resistant complex, , , and strains was determined by microdilution in iron-depleted Mueller-Hinton broth. The MICs against , , and were 1, 0.25, and 0.5 mg/liter, respectively. Against , the MIC was 1 mg/liter for the group harboring OXA-48-like, 2 mg/liter for the group harboring KPC-3, and 8 mg/liter for the group harboring TEM/SHV ESBL, NDM, and KPC-2.

摘要

头孢他啶-去铁胺的活性针对碳青霉烯类耐药的革兰氏阴性菌。在这项研究中,通过在缺铁 Mueller-Hinton 肉汤中的微量稀释法来确定头孢他啶-去铁胺对特征性碳青霉烯类耐药的 、 、 和 菌株的活性。对 、 、 和 的 MIC 分别为 1、0.25 和 0.5mg/l。对于携带 OXA-48 样、KPC-3 的组,头孢他啶-去铁胺的 MIC 分别为 1mg/l 和 2mg/l,对于携带 TEM/SHV ESBL、NDM 和 KPC-2 的组,MIC 为 8mg/l。

相似文献

1
ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and with Defined Extended-Spectrum β-Lactamases and Carbapenemases.ARGONAUT-I 研究:头孢他啶罗(S-649266),一种新型的具有铁载体结构的头孢菌素,对革兰氏阴性菌的活性,包括碳青霉烯类耐药非发酵菌和具有明确的扩展谱β-内酰胺酶和碳青霉烯酶。
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01801-18. Print 2019 Jan.
2
In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.2015-2016 年北美和欧洲临床实验室分离的革兰氏阴性杆菌的体外药敏试验:SIDERO-WT-2015。
Int J Antimicrob Agents. 2019 Apr;53(4):456-466. doi: 10.1016/j.ijantimicag.2018.11.007. Epub 2018 Nov 22.
3
In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.在加拿大重症监护病房中分离的革兰氏阴性杆菌的体外活性研究:新型铁载体头孢菌素头孢地尔。
Diagn Microbiol Infect Dis. 2020 May;97(1):115012. doi: 10.1016/j.diagmicrobio.2020.115012. Epub 2020 Feb 4.
4
In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).头孢地尔罗的体外活性,一种铁载体头孢菌素,针对最近收集的临床相关碳青霉烯类药物不敏感的革兰氏阴性杆菌,包括丝氨酸碳青霉烯酶和金属β-内酰胺酶产生的分离株(SIDERO-WT-2014 研究)。
Int J Antimicrob Agents. 2019 Feb;53(2):177-184. doi: 10.1016/j.ijantimicag.2018.10.007. Epub 2018 Oct 26.
5
In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria.S-649266,一种儿茶酚取代的铁载体头孢菌素,在测试时对非发酵革兰氏阴性菌的体外抗菌活性。
J Antimicrob Chemother. 2016 Mar;71(3):670-7. doi: 10.1093/jac/dkv402. Epub 2015 Dec 7.
6
Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients.重症监护患者肠道菌群中产碳青霉烯类耐药革兰阴性杆菌的出现。
Antimicrob Agents Chemother. 2013 Mar;57(3):1488-95. doi: 10.1128/AAC.01823-12. Epub 2013 Jan 14.
7
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.头孢地尔:一种具有抗碳青霉烯类和多药耐药革兰氏阴性杆菌活性的铁载体头孢菌素。
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
8
Activity of Cefiderocol Against , , and Endemic to Medical Centers in New York City.头孢地尔在纽约市医疗中心的流行情况及对 、 、的活性。
Microb Drug Resist. 2020 Jul;26(7):722-726. doi: 10.1089/mdr.2019.0298. Epub 2020 Feb 7.
9
Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.头孢地尔(S-649266)对从希腊医院住院患者中分离出的耐碳青霉烯革兰氏阴性菌的活性。
J Antimicrob Chemother. 2017 Jun 1;72(6):1704-1708. doi: 10.1093/jac/dkx049.
10
Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models.头孢地尔洛的药效学研究,一种新型的注射用铁载体头孢菌素,在鼠大腿和肺部感染模型中的研究。
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.02031-18. Print 2019 Sep.

引用本文的文献

1
Global Epidemiology and Antimicrobial Resistance of Klebsiella Pneumoniae Carbapenemase (KPC)-Producing Gram-Negative Clinical Isolates: A Review.产肺炎克雷伯菌碳青霉烯酶(KPC)革兰阴性临床分离株的全球流行病学及抗菌药物耐药性:综述
Microorganisms. 2025 Jul 19;13(7):1697. doi: 10.3390/microorganisms13071697.
2
Resistance to oxyimino-cephalosporins conferred by an alternative mechanism of hydrolysis by the -derived cephalosporinase-33 (ADC-33), a class C β-lactamase present in carbapenem-resistant (CR).由源自头孢菌素酶-33(ADC-33)的另一种水解机制赋予的对氧亚氨基头孢菌素的耐药性,ADC-33是一种存在于耐碳青霉烯类肠杆菌科细菌(CR)中的C类β-内酰胺酶。
mBio. 2025 Jun 11;16(6):e0028725. doi: 10.1128/mbio.00287-25. Epub 2025 May 16.
3
ARGONAUT-IV: susceptibility of carbapenemase-producing to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten.ARGONAUT-IV:产碳青霉烯酶菌株对口服双环硼酸酯β-内酰胺酶抑制剂来达硼巴坦与头孢布烯联合用药的敏感性。
Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0112724. doi: 10.1128/aac.01127-24. Epub 2024 Oct 30.
4
Effects of different carbapenemase and siderophore production on cefiderocol susceptibility in .不同碳青霉烯酶产生及铁载体生成对头孢地尔敏感性的影响
Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0101924. doi: 10.1128/aac.01019-24. Epub 2024 Oct 29.
5
In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series.产 KPC 肺炎克雷伯菌感染中新型β-内酰胺/β-内酰胺酶抑制剂合剂耐药性的体内发展:病例系列。
Eur J Clin Microbiol Infect Dis. 2024 Dec;43(12):2407-2417. doi: 10.1007/s10096-024-04958-w. Epub 2024 Oct 10.
6
Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria.头孢地尔治疗产VIM型革兰阴性菌感染
Antibiotics (Basel). 2024 Sep 12;13(9):874. doi: 10.3390/antibiotics13090874.
7
Efflux pump-mediated resistance to new beta lactam antibiotics in multidrug-resistant gram-negative bacteria.多药耐药革兰氏阴性菌中外排泵介导的对新型β-内酰胺类抗生素的耐药性
Commun Med (Lond). 2024 Aug 29;4(1):170. doi: 10.1038/s43856-024-00591-y.
8
ARGONAUT-III and -V: susceptibility of carbapenem-resistant and multidrug-resistant to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime.ARGONAUT-III 和 -V:碳青霉烯类耐药和多重耐药对双环硼酸β-内酰胺酶抑制剂替加环素与头孢吡肟联合用药的敏感性。
Antimicrob Agents Chemother. 2024 Sep 4;68(9):e0075124. doi: 10.1128/aac.00751-24. Epub 2024 Aug 12.
9
Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.头孢地尔罗治疗严重需氧革兰氏阴性细菌感染:技术评估以提供一种新的订阅式支付模式。
Health Technol Assess. 2024 Jun;28(28):1-238. doi: 10.3310/YGWR4511.
10
Friends or foes? Novel antimicrobials tackling MDR/XDR Gram-negative bacteria: a systematic review.朋友还是敌人?应对多重耐药/广泛耐药革兰氏阴性菌的新型抗菌药物:一项系统综述
Front Microbiol. 2024 May 10;15:1385475. doi: 10.3389/fmicb.2024.1385475. eCollection 2024.

本文引用的文献

1
Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV.快速分子诊断有助于经验性使用头孢他啶/阿维巴坦和头孢洛扎/他唑巴坦治疗铜绿假单胞菌:PRIMERS IV。
Clin Infect Dis. 2019 May 17;68(11):1823-1830. doi: 10.1093/cid/ciy801.
2
Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters.新型头孢菌素类抗生素头孢地尔通过人体药物转运体产生的药物相互作用。
Eur J Clin Pharmacol. 2018 Jul;74(7):931-938. doi: 10.1007/s00228-018-2458-9. Epub 2018 Apr 7.
3
Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016.2014 年至 2016 年全球范围内收集的碳青霉烯类药物不敏感和多重耐药革兰氏阴性杆菌的头孢菌素类抗生素头孢地尔的活性。
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01968-17. Print 2018 Feb.
4
Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model.头孢他啶美罗培南复方制剂在铜绿假单胞菌中性粒细胞减少小鼠大腿模型中的药效学研究。
Int J Antimicrob Agents. 2018 Feb;51(2):206-212. doi: 10.1016/j.ijantimicag.2017.10.008. Epub 2017 Oct 27.
5
Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria.头孢地尔的抗菌特性,一种新型的铁载体头孢菌素,针对革兰氏阴性菌。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01454-17. Print 2018 Jan.
6
Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis.健康受试者、不同程度肾功能受试者以及复杂性尿路感染或急性单纯性肾盂肾炎患者中铁载体头孢菌素头孢地尔的群体药代动力学分析。
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01391-17. Print 2018 Feb.
7
A Prospective Observational Study of the Epidemiology, Management, and Outcomes of Skin and Soft Tissue Infections Due to Carbapenem-Resistant .一项关于耐碳青霉烯类皮肤和软组织感染的流行病学、管理及结局的前瞻性观察研究
Open Forum Infect Dis. 2017 Jul 27;4(3):ofx157. doi: 10.1093/ofid/ofx157. eCollection 2017 Summer.
8
New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?新型革兰氏阴性菌感染治疗药物:重现奇迹还是虚幻曙光?
Clin Microbiol Infect. 2017 Oct;23(10):704-712. doi: 10.1016/j.cmi.2017.09.001. Epub 2017 Sep 8.
9
Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam.阿维巴坦恢复嗜麦芽寡养单胞菌临床分离株对氨曲南的敏感性。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00777-17. Print 2017 Oct.
10
Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens.新型铁载体头孢菌素头孢地尔的活性对多重耐药革兰氏阴性病原体。
Eur J Clin Microbiol Infect Dis. 2017 Dec;36(12):2319-2327. doi: 10.1007/s10096-017-3063-z. Epub 2017 Jul 26.